ABBV Jan 2025 240.000 call
| Previous Close | 1.2400 |
| Open | 1.2400 |
| Bid | 1.2200 |
| Ask | 1.8000 |
| Strike | 240.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 1.2400 - 1.2400 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 107 |
- Motley Fool
Better Buy: AbbVie vs. Johnson & Johnson
AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) did something many other stocks didn't last year. After all, these stocks offer a track record of earnings growth and dividend increases. The company's mega-blockbuster immunology drug, Humira, recently started facing competition in the U.S. And AbbVie predicts that this will result in a 37% decline in the drug's sales this year.
- Zacks
Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL
Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951
- Motley Fool
2 High-Yield Dividend Stocks You Won't Regret Buying Right Now
High-yield dividend stocks can be great for managing the ongoing reset in global equity markets. Which high-yield dividend stocks are worth buying right now? Read on to find out more about these above-average passive income opportunities.
